Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of Phase III study ETV-022 in nucleoside-naive patients

被引：0
|
作者：
Chang, TT
Gish, R
de Man, R
Gadano, A
Sollano, J
Han, KH
Goodman, Z
Zhu, J
Cross, A
DeHertogh, D
Apelian, D
机构：
[1] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[2] Calif Pacific Med Ctr, San Francisco, CA USA
[3] Erasmus Univ Hosp, Rotterdam, Netherlands
[4] H22 Hosp, Buenos Aires, DF, Argentina
[5] Univ Santo Tomas, Manila, Philippines
[6] Yonsei Univ, Coll Med, Severance Hosp, Seoul, South Korea
[7] Armed Forces Inst Pathol, Washington, DC 20306 USA
[8] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
来源：
ANTIVIRAL THERAPY | 2004年 / 9卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：H21 / H22
页数：2
相关论文
共 50 条
  • [1] Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: Results of phase III study ETV-022 in nucleoside-naive patients
    Chang, TT
    Gish, R
    de Man, R
    Gadano, A
    Sollano, J
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    Dehertogh, D
    Apelian, D
    HEPATOLOGY, 2004, 40 (04) : 193A - 193A
  • [2] Entecavir is superior to lamivudine for the treatment of chronic hepatitis B (CHB): Results of a phase 3 Chinese study (ETV-023) in nucleoside-naive patients
    Yao, G.
    Chen, C.
    Lu, W.
    Ren, H.
    Tan, D.
    Wang, Y.
    Xu, D.
    Jiang, M.
    Liu, J.
    Xu, D.
    MacDonald, L.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S193 - S193
  • [3] Entecavir (ETV) is superior to lamivudine (LVD) for the treatment of chronic hepatitis B (CHB): results of a phase 3 Chinese study (ETV-023) in nucleoside-naive patients
    Yao, Guangbi
    Chen, Chengwei
    Lu, Weilun
    Ren, Hong
    Tan, Deming
    Wang, Yuming
    Xu, Daozheng
    Liu, Jessica
    Xu, Dong
    Macdonald, Laurie
    Jiang, Michael
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A126 - A126
  • [4] Four-year entecavir treatment in nucleoside-naive HBeAg(+) patients: Results from studies ETV-022 and-901
    Han, Steven
    Chang, Ting-Tsung
    Chao, You-Chen
    Yoon, Seung-Kew
    Gish, Robert G.
    Cheinquer, Hugo
    Carrillho, Flair Jose
    Zhong, Hui
    Brett-Smith, Helena
    Hindes, Robert
    HEPATOLOGY, 2007, 46 (04) : 654A - 654A
  • [5] Decline in Hepatitis B Surface Antigen Levels With Entecavir Treatment in HBeAg-Positive Nucleoside Naive Chronic Hepatitis B Patients- Results From Phase III Study ETV-022
    Gish, Robert
    Chang, Ting-Tsung
    Lai, Ching-Lung
    De Man, Robert A.
    Gadano, Adrien
    Yu, Song
    Llamoso, Cyril
    Tang, Hong
    GASTROENTEROLOGY, 2012, 142 (05) : S917 - S917
  • [6] Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: Results of phase III trial ETV-027.
    Shouval, D
    Lai, CL
    Cheinquer, H
    Lok, A
    DeHertogh, D
    Wilber, R
    Cross, A
    Zink, R
    Fernandes, L
    HEPATOLOGY, 2004, 40 (04) : 728A - 728A
  • [7] Sustained response off-treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside-naive, HBEAG(+) patients: 24-week follow-up results of phase 3 study ETV-022
    Gish, RG
    De Man, RA
    Pedersen, C
    Bialkowska, J
    Chang, TT
    Apelian, D
    Zhu, J
    Cross, A
    Wilber, R
    JOURNAL OF HEPATOLOGY, 2005, 42 : 177 - 177
  • [8] Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: Results of phase III study ETV-026
    Sherman, M
    Yurdaydin, C
    Sollano, J
    Silva, M
    Goodman, Z
    Chen, L
    Cross, A
    Dehertogh, D
    Hindes, R
    HEPATOLOGY, 2004, 40 (04) : 664A - 664A
  • [9] Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of Phase III study ETV-026
    Sherman, M
    Yurdaydin, C
    Sollano, J
    Silva, M
    Goodman, Z
    Chen, L
    Cross, A
    DeHertogh, D
    Hindes, R
    ANTIVIRAL THERAPY, 2004, 9 (06) : H22 - H23
  • [10] Entecavir (ETV) is well tolerated for the treatment of nucleoside-naive and Lamivudine-refractory chronic hepatitis B: phase 2/3 safety results
    Gigi, M. R.
    Manns, M.
    Cooney, E.
    Hindes, R.
    Cross, A.
    Wilber, R.
    LIVER INTERNATIONAL, 2006, 26 : 56 - 56
12345